William Harvey Research
Preclinical contract research organisation (est. 1990) providing bespoke preclinical in vivo and in vitro efficacy, verification and interpretation services across cardiovascular, inflammatory, renal, metabolic and pain indications. Offers scientific consultancy, a large catalogue of validated disease models (including transgenic strains), and organises scientific conferences and training.
Industries
Nr. of Employees
small (1-50)
William Harvey Research
London, England, United Kingdom, Europe
Services
Execution of validated in vivo and in vitro studies across a broad catalogue of disease models to support preclinical drug evaluation.
One-to-one consultation with senior scientists to design appropriate preclinical studies and advise on model selection and endpoints.
Programme development, speaker coordination, registration management, venue and logistics management and on-site hosting for scientific meetings.
Provision of specialist training courses in preclinical imaging and related skills (course dates published when scheduled).
Execution of validated in vivo and in vitro studies across a broad catalogue of disease models to support preclinical drug evaluation.
One-to-one consultation with senior scientists to design appropriate preclinical studies and advise on model selection and endpoints.
Programme development, speaker coordination, registration management, venue and logistics management and on-site hosting for scientific meetings.
Provision of specialist training courses in preclinical imaging and related skills (course dates published when scheduled).
Expertise Areas
- Preclinical contract research
- Disease modelling and preclinical efficacy testing
- Cardiovascular and pulmonary vascular disease modelling
- Inflammation and sepsis models
Key Technologies
- Rodent in vivo disease models
- Transgenic and genetically modified animal models
- Chemically-induced models (LPS, DSS, TNBS, streptozotocin, bleomycin)
- Surgical/procedural models (CLP, LAD ligation, UUO, ischemia-reperfusion)
News & Updates
Annual symposium on prostacyclin science and pulmonary vascular disease. Scheduled for Friday 13 and Saturday 14 March 2026 at The Royal Society, London. Standard registration fee noted on the event page.
20th JVMS held 7-8 March 2025 at The Royal Society, London; programme and recorded presentations were made available to attendees.
Annual symposium on prostacyclin science and pulmonary vascular disease. Scheduled for Friday 13 and Saturday 14 March 2026 at The Royal Society, London. Standard registration fee noted on the event page.
20th JVMS held 7-8 March 2025 at The Royal Society, London; programme and recorded presentations were made available to attendees.